Active — Not RecruitingNot Applicable

Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation

France552 participantsStarted 2023-06-26

Plain-language summary

CMV disease remains the most frequent infectious complication post-transplant and it is associated to high morbidity and even mortality. Global efforts from both transplant physicians and researchers in the field is needed to better characterize the host-virus interactions in the transplant setting, with the aim of decreasing the burden of disease and improve the well-being of patients. "HORUS" (Casting light on HOst-cytomegaloviRUs interaction in Solid organ transplantation) study is a European research project, funded by the European Commission (Horizon Europe) involving 16 partners in seven European countries (France, Spain, Czech Republic, Belgium, Switzerland, Germany and Italy) aiming to better characterize the host-CMV interactions in SOT recipients. The first aim of HORUS study will be to build a European cohort of SOT recipients including clinical characterization and the constitution of a biocollection, which is the aim of HORUS cohort, in order to perform biological, immunological, gene expression, viral kinetics and deep viral genome characterization in the global European HORUS project to improve our understanding of the development of a CMV immune response in the context of immunosuppression.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

A cohort 1 of solid-organ transplant recipients at day 0 of transplantation will be included: * Consecutive patients meeting the following inclusion criteria will be included: * Men and women, * Age \>= 18 years receiving a (living or deceased donor) kidney, lung, liver, and heart allograft, * written informed consent obtained from subject, * ability to understand and give their written consent, * affiliated to health insurance. * Exclusion criteria would be: * D-R- recipients, * participant unable or unwilling to comply with study procedures, * subjects who are legally detained in an official institution. A cohort 2 of solid-organ transplant recipients at day 0 of infection: * Consecutive patients meeting the following inclusion criteria will be included: * Men and women, * Age \>= 18 years receiving a (living or deceased donor) kidney, lung, liver, and heart allograft * written informed consent obtained from subject, * ability to understand and give their written consent, * affiliated to health insurance, * post-transplant CMV infection episode. * Exclusion criteria would be: * D-R- recipients, * participant unable or unwilling to comply with study procedures, * subjects who are legally detained in an official institution.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Biobank inventory for cohort 1 : day 0 of transplantation

Timeframe: from day of graft (inclusion day) to month 24

Biobank inventory for cohort 1 : day 0 of transplantation

Timeframe: from day of graft (inclusion day) to month 24

Biobank inventory for cohort 1 : day 0 of transplantation

Timeframe: from day of graft (inclusion day) to month 24

Biobank inventory for cohort 1 : day 0 of transplantation

Timeframe: from day of graft (inclusion day) to month 24

Biobank inventory for cohort 1 : day 0 of transplantation

Timeframe: from day of graft (inclusion day) to month 24

Biobank inventory for cohort 2 : day 0 of infection

Timeframe: from day of infection (inclusion day) to month 12

Biobank inventory for cohort 2 : day 0 of infection

Timeframe: from day of infection (inclusion day) to month 12

Trial details

NCT IDNCT05701228

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Cytomegalovirus Infections trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Biobank inventory for cohort 1 : day 0 of transplantation

Timeframe: from day of graft (inclusion day) to month 24

Biobank inventory for cohort 1 : day 0 of transplantation

Timeframe: from day of graft (inclusion day) to month 24

Biobank inventory for cohort 1 : day 0 of transplantation

Timeframe: from day of graft (inclusion day) to month 24

Biobank inventory for cohort 1 : day 0 of transplantation

Timeframe: from day of graft (inclusion day) to month 24

Biobank inventory for cohort 1 : day 0 of transplantation

Timeframe: from day of graft (inclusion day) to month 24

Biobank inventory for cohort 2 : day 0 of infection

Timeframe: from day of infection (inclusion day) to month 12

Biobank inventory for cohort 2 : day 0 of infection

Timeframe: from day of infection (inclusion day) to month 12